CJC vs ipamorelin: how these two growth hormone peptides differ in half-life, dosing, and research use, plus safety notes and what to ask a clinician.
CJC-1295 and ipamorelin are both growth hormone–releasing research peptides, but they are not interchangeable. CJC-1295 is a GHRH analog that keeps growth hormone (GH) elevated for days when it includes the drug affinity complex, while ipamorelin is a selective ghrelin-receptor agonist that mimics a natural GH pulse and clears within a few hours. Neither peptide is FDA-approved for human use in the United States, and both are sold online as research chemicals.
What CJC-1295 and Ipamorelin Actually Are
CJC-1295 is a synthetic analog of growth hormone–releasing hormone (GHRH). It binds GHRH receptors in the pituitary and signals the gland to release GH. The version known as CJC-1295 with DAC carries a maleimide group that binds albumin in the blood, which is why it stays active for days instead of minutes.
Ipamorelin is a five-amino-acid peptide that acts on the ghrelin/growth hormone secretagogue receptor. Rather than prolonging GH release, it triggers a distinct pulse that looks closer to what a healthy pituitary produces on its own.
- Class: CJC-1295 is a GHRH analog; ipamorelin is a ghrelin receptor agonist.
- Duration: CJC-1295 with DAC lasts roughly 6 to 8 days; ipamorelin lasts about 2 hours.
- Selectivity: Ipamorelin is noted for how little it affects cortisol, prolactin, and appetite compared with older secretagogues.
- Route: Both are studied as subcutaneous injections.
Head-to-Head Comparison
| Feature | CJC-1295 (with DAC) | Ipamorelin |
|---|---|---|
| Mechanism | GHRH receptor agonist | Ghrelin / GHS-R agonist |
| Half-life | About 6–8 days | About 2 hours |
| GH release pattern | Sustained, raised baseline | Short, discrete pulse |
| Common research dose | 1–2 mg per week | 100–300 mcg, 1–3 times daily |
| Appetite effect | Minimal | Minimal (unlike GHRP-6) |
| FDA-approved for human use | No | No |
CJC-1295 with DAC stays active for about a week, while ipamorelin clears the bloodstream in roughly two hours. That single difference drives most of the protocol design people argue about.
CJC-1295 With DAC vs Without DAC
Most confusion about cjc-1295 vs ipamorelin actually comes from two different molecules sharing one name. CJC-1295 with DAC is the long-acting form. CJC-1295 without DAC, often labeled mod GRF (1-29), has a half-life closer to 30 minutes.
CJC-1295 without DAC behaves much more like ipamorelin in practice, which is why the two are frequently stacked and injected together. The DAC version is usually researched alone, once or twice a week.
| Version | Half-life | Typical research schedule |
|---|---|---|
| CJC-1295 with DAC | 6–8 days | 1–2 mg once or twice weekly |
| CJC-1295 without DAC (mod GRF 1-29) | About 30 minutes | 100 mcg, 1–3 times daily |
| Ipamorelin | About 2 hours | 100–300 mcg, 1–3 times daily |
How People Stack and Dose Them in Research
Community protocols are not clinical recommendations, and dosing information circulating online has not been verified by any regulator. With that caveat, the most common research design pairs a short-acting GHRH analog with a ghrelin agonist:
- 100 mcg of CJC-1295 without DAC plus 100–300 mcg of ipamorelin.
- Injected subcutaneously two to three times daily.
- Timed before meals and away from food, since insulin and free fatty acids blunt GH release.
- Cycled for 8–12 weeks, followed by a break.
Communities on Reddit, where people search ipamorelin vs cjc and ipamorelin or cjc 1295 constantly, mostly debate timing, fasting windows, and whether the long-acting DAC version is worth the prolonged exposure.
What Research Suggests About Effects
Published human data is thin. A 2006 study of CJC-1295 with DAC in healthy adults found dose-dependent increases in GH and IGF-1 that persisted for up to 28 days after a single injection. Ipamorelin has been studied mainly in animals, where it raised GH without meaningfully changing cortisol or prolactin.
People comparing cjc-1295 ipamorelin vs tesamorelin are usually weighing a gray-market research peptide against an FDA-approved GHRH analog used for HIV-associated lipodystrophy. Tesamorelin has completed large human trials; CJC-1295 and ipamorelin have not.
The cjc-1295 ipamorelin vs hgh question matters too. Exogenous HGH replaces your own production and can suppress the pituitary, while secretagogues attempt to work with it. That is a real mechanistic difference, not a marketing one.
Side Effects and Safety Considerations
Reported side effects of both peptides include injection-site irritation, flushing, headache, tingling or numbness in the hands, water retention, and fatigue. Long-acting CJC-1295 may keep GH and IGF-1 elevated for days, and chronically high IGF-1 is a legitimate concern in the medical literature.
GH-raising peptides are generally avoided by people with active cancer, pituitary tumors, uncontrolled diabetes, or diabetic retinopathy. Anyone considering them should talk with a physician rather than relying on forum posts.
No GH-releasing peptide sold online as a research chemical has been evaluated by the FDA for safety, purity, or dosing in humans.
Legal Status and Sourcing
Neither CJC-1295 nor ipamorelin is approved as a drug in the US, and both are typically sold with “not for human consumption” labels. That means no pharmacy oversight, no guaranteed purity, and little recourse if a vial is mislabeled. Third-party certificates of analysis are common but are not a substitute for regulation.
Comparing ipamorelin cjc 1295 vs sermorelin or researching aod-9604 vs cjc-1295 ipamorelin usually leads back to the same conclusion: approved alternatives have a far stronger evidence base than anything available for gray-market peptides.
Bottom Line
Ipamorelin produces a short, selective GH pulse, and CJC-1295 with DAC produces a long, sustained rise. The short-acting form of CJC-1295 is often stacked with ipamorelin because their timing lines up; the DAC version is not. Neither is FDA-approved, and neither should be started without medical supervision.
Frequently Asked Questions
What is the main difference between CJC-1295 and ipamorelin?
The main difference is mechanism and duration. CJC-1295 is a GHRH analog that signals the pituitary through GHRH receptors and, with DAC, stays active for roughly 6 to 8 days. Ipamorelin is a ghrelin receptor agonist that triggers a short GH pulse and clears in about 2 hours.
Can you take CJC-1295 and ipamorelin together?
In research and community settings, the short-acting form of CJC-1295 is commonly stacked with ipamorelin because their half-lives are similar and their mechanisms complement each other. There are no large human trials confirming safety or benefit for this combination. Neither peptide is FDA-approved, so a doctor should be involved in any decision.
Are CJC-1295 and ipamorelin legal in the United States?
Neither is FDA-approved for human use, and both are typically sold as research chemicals labeled “not for human consumption.” Buying them is not automatically illegal, but the products are unregulated, so purity and dosing are not verified. Prescription alternatives such as tesamorelin are the only GH-related peptides with FDA approval.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.